Candesartan for the management of heart failure: More than an alternative

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 14, 2006, Pages 1945-1956

  McKelvie, Robert S ^a  

^a HHSC General Division   (Canada)

Author keywords

Angiotensin receptor blockers; Candesartan; Heart failure; Systolic dysfunction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN POTASSIUM; PLACEBO; POTASSIUM; SPIRONOLACTONE; TASOSARTAN; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; MORBIDITY; MORTALITY; NONHUMAN; POTASSIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VASOCONSTRICTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; CLINICAL TRIALS; EXPERT TESTIMONY; HEART FAILURE, CONGESTIVE; HUMANS; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME;

EID: 33749393238     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.14.1945     Document Type: Article

References (64)

1. SWEDBERG K, CLELAND J, DARGIE H et al.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. (2005) 26:1115-1140.
2. HUNT SA, ABRAHAM WT, CHIN MH et al.: ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation (2005) 20:1825-1852.
3. MOSTERD A, HOES AW, DE BRUYNE MC et al.: Prevalence of heart failure and left ventricular dysfunction in the general population. Eur. Heart J. (1999) 20:447-455.
4. MCDONAGH TA, MORRISON CE, LAWRENCE A et al.: Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet (1997) 350:829-833.
5. CLELAND JG, KHAND A, CLARK A: The heart failure epidemic: exactly how big is it? Eur. Heart J. (2001) 22:623-626.
6. CEIA F, FONSECA C, MOTA T et al.: Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. (2002) 4:531-539.
7. OWAN TE, REDFIELD MM: Epidemiology of diastolic heart failure. Prog. Cardiovasc. Dis. (2005) 47(5):320-332.
8. MCKELVIE RS: Cardiovascular disorders: heart failure. Clin. Evid. (2004) 12:115-143.
9. FLATHER M, YUSUF S, KOBER L et al. FOR THE ACE-INHIBITOR MYOCARDIAL INFARCTION COLLABORATIVE GROUP: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet (2000) 355:1575-1581.
10. BROPHY JM, JOSEPH L, ROULEAU JL: β-blockers in congestive heart failure: a Bayesian mesa-analysis. Ann. Intern. Med. (2001) 134:550-560.
11. WHORLOW SL, KRUM H: Meta-analysis of effect of β-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. Am. J. Cardial. (2000) 86:886-889.
12. PACKER M, COATS A, FOWLER MB: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344:1651-1658.
13. PITT B, ZANNAD F, REMME WJ et al. FOR THE RANDOMIZED ALDACTONE EVALUATION STUDY INVESTIGATORS: The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. (1999) 341:709-717,
14. SCHAUFEL M, SWEDBERG K, KOSTER M et al.: Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur. Heart J. (2005) 25:300-307.
15. LEE DS, AUSTIN PC, ROULEAU JL et al.: Predicting mortality among patients hospitalized for heart failure. Derivation and validation of a clinical model. JAMA (2003) 290(19):2581-2587.
16. MASSI BM, FABI MR: Clinical trials in diastolic heart failure. Prog. Cardiov. Dis. (2005) 47(6):389-395.
17. BART BA, ERTL G, HELD P et al.: Contemporary management of patients with left ventricular systolic dysfunction: results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur. Heart J. (1999) 20:1182-1190.
18. JORDE UP, ENNEZAT PV, LISKER J et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE mediated formation of angiotensin ii in chronic heart failure. Circulation (2000) 10:844-846.
19. URATA H, HEALY B, STEWART RW et al.: Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. (1990) 66:883-890.
20. MACFADYEN RJ, LEE AF, MORTON JJ et al.: How often are angiotensin II and aldosterone concentrations raised during chronic ACE-inhibitor treatment in cardiac failure? Heart (1999) 82:57-61.
21. PITT B, POOLE-WILSON P, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582-1587.
22. DICKSTEIN K, KJEKSUHUS J, THE OPTIMAAL STEERING COMMITTEE: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet (2002) 360:752-760.
23. COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345:1667-1675.
24. PFEFFER MA, MCMURRAY JV, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349:1893-1906.
25. SEVER P: Candesartan cilextil: a new, long-acting, effective angiotensin II Type 1 receptor blocker. J. Hum. Hypertens. (1997) 1(Suppl. 2):S91-S95.
26. PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet (2003) 362:759-766.
27. SHIBOUTA Y, INADA Y, OJIMA M et al.: Pharmacalogical profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1 2′-(1H-tetrazol-5-yl) biphenyl-4-yl]-1Hbenzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+-) 1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-l- 2′-(1H-tetrazol-5-yl) biphenyl-4yl]methyl]-1H-benzimidazole-7-carboxylate (TCV 116). J. Pharmacol. Exp. Ther. (1993) 266:114-120.
28. CHIU AT, MCCALL DE, PRICE WA et al.: Nonpeptide angiotensin II receptor antagonists.VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J. Pharm. Exp. Ther. (1990) 252:711-718.
29. UNGER T: Pharmacology of AT1-receptor blockers. Blood Press. (2001) 10(Suppl. 3):5-10.
30. MORIMOTO S, OGIHARA T: TCV-116: a new angiotensin type-1 receptor antagonist. Cardiov. Drug Rev. (1994) 12:153-164.
31. VAN LIER JJ, VAN HEININGEN PNM, SUNZEL M: Absorption metabolism and excretion of candesartan and candesartan cilexetil in healthy volunteers. J. Hum. Hypertens. (1997) 11(Suppl. 2):S27-S28.
32. NISHIKAWA K, NAKA T, CHATANI F, YOSHIMURA Y: Candesartan cilexetil: a review of its preclinical pharmacology. J. Hum. Hypertens. (1997) 11(Suppl. 2):S9-S17.
33. HÜBNER R, HOGEMANN AM, SUNZEL M et al.: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J. Hum. Hypertens. (1997) 11(Suppl.2):S19-S25.
34. OJIMA M, INADA Y, SHIBOUTA Y et al.: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. J. Pharmacol. (1997) 319:137-146.
35. FIERENS F, VANDERHEYDEN PM, DE BACKER JP et al.: Binding of the antagonist [3H] candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells. Eur. J. Pharmacol. (1999) 367:413-422.
36. TIMMERMANS PBMWM: Pharmacological properties of angiotensin II receptor antagonists. Can. J. Cardiol. (1999) 15(Suppl. F):F26-F28.
37. MORSING P, BRANDT-ELIASSON U, ABRAHAMSSON T: Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension (1999) 33:1406-1413.
38. BELZ GG, MALERCZYK C, ROLL S et al.: Angiotensin-II antagonist and radiogland receptor assay following various doses of candesartan cilextil in humans. J. Hypertens. (1996) 14(Suppl. 1):S134.
39. MALERCZYK C, FUCHS B, BELZ GG et al.: Angiotensin II antagonist and plasma radioreceptor-kinetics of candesartan in man. Br. J. Clin. Pharmacol. (1998) 45:567-573.
40. GRANGER CB, ERTL G, KUCH J et al.: Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. (2000) 139:609-617.
41. MITROVIC V, WILLENBROCK R, MIRIC M et al.: Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones and clinical symptoms in patient with congestive heart failure. Am. Heart J. (2004) 145:D1-D9.
42. RIEGGER GAJ, BUOZO H, PETR P et al.: Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilextil. Circulation (1999) 100:2224-2230.
43. MATSUMORI A ON BEHALF OF THE ASSESSMENT OF RESPONSE TO CANDESARTAN IN HEART FAILURE IN JAPAN (ARCH-J) STUDY INVESTIGATORS: Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur. J. Heart Fail. (2003) 5:669-677.
44. MCKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation (1999) 100:1056-1064.
45. MCKELVIE RS, ROULEAU JL, WHITE M et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. Eur. Heart J. (2003) 24:1727-1734.
46. SWEDBERG K, PFEFFER M, GRANGER C et al. FOR THE CHARM-PROGRAMME INVESTIGATORS: Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) - rationale and design. J. Card. Fail. (1999) 5:276-282.
47. GRANGER CB, MCMURRAY JJV, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772-776.
48. MCMURRAY JJV, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767-771.
49. YUSUF S, PFEFFER MA, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved Trial. Lancet (2003) 362:777-781.
50. YOUNG JB, DUNLAP ME, PFEFFER MA et al.: Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 110:2618-2183.
51. SOLOMON SD, WANG D, FINN P et al.: Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation (2004) 110:2180-2183.
52. DEMERS C, MCMURRAY JJV, SWEDBERG K et al.: Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA (2005) 294:1794-1798.
53. YUSUF S, OSTERGREN JB, GERSTEIN HC et al.: Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation (2005) 112:48-53.
54. O'MEARA E, LEWIS E, GRANGER C et al.: Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. J. Heart Fail. (2005) 7:650-656.
55. O'MEARA E, SOLOMON S, MCMURRAY J et al.: Effect of candesartan on New York Heart Association functional class: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. Heart J. (2004) 25:1920-1926.
56. DUCHARME A, SWEDBERG K, PFEFFER M et al.: Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am. Heart J. (2006) 151:985-991.
57. SUSKIN N, MCKELVIE RS, BURNS RJ et al.: Glucose and insulin abnormalities relate to functional capacity in patients with patients with congestive heart failure. Eur. Heart J. (2000) 21:1368-1375.
58. LITHELL H, HANSSON L, SKOOG I et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypert. (2003) 21(5):875-886.
59. SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke (2003) 34:1699-1703.
60. TRONVIK E, STOVNER LJ, HELDE G et al.: Prophylactic treatment of migraine with an angiotensin ii receptor blocker: a randomized controlled trial. JAMA (2003) 289:65-69.
61. MIMRAN A, ALFARO V: Candesartan: nephroprotective effects and treatment of diabetic nephropathy. Drugs of Today (2003) 39:439-450.
62. MOGENSEN C, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of duel blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. (2000) 321:1440-1444.
63. 1 receptor in pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. (2006) Suppl.: In press.
64. THE DIRECT PROGRAMME STUDY GROUP: The Diabetic Retinopathy Candesartan Trials (DIRECT) programme, rationale and study design. J. Renin Angiotensin Aldosterone Syst. (2002) 3:255-261.